Stephan A. Grupp, MD, PhD

Stephan A. Grupp, MD, PhD, is director of the Cancer Immunotherapy Frontier Program, director of Translational Research for the Center for Childhood Cancer Research at CHOP and medical director of the Stem Cell Laboratory. 

Areas of Expertise: Development of engineered T cell therapies such as CTL019, Novel leukemia therapy, Stem cell transplants, Treatment of high-risk neuroblastoma
Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

  • Background

    As an attending physician in the Cancer Center, director of the Cancer Immunotherapy Frontier Program, director of Translational Research of the Center for Childhood Cancer Research, and the director of the Stem Cell Laboratory, I take on many roles here at CHOP. But in each of them, I’m a pediatric oncologist working to improve outcomes for children battling difficult cancers. I trained at Harvard, at Boston Children’s and the Dana Farber Cancer Institute, and came to CHOP in 1996. I also have the privilege of working with our Pediatric Hematology/Oncology trainees as Fellowship Director.

    Working with our colleagues at the University of Pennsylvania, we have recently opened a phase I clinical trial called CART19. We’re using genetically modified T cells in this trial to treat patients with B cell cancers such as ALL, B cell non-Hodgkin lymphoma (NHL), the adult disease chronic lymphocytic leukemia and other B cell malignancies. T cells have the potential to kill cancer cells, but in patients with cancer, they’re not doing their job. By modifying them we can make the cells behave differently so they’ll attack cancer cells, using an engineered targeting protein called a chimeric antigen receptor (CAR). Initial results show that this could be an effective therapy for patients with B cell cancers. Indeed, our initial results show some of the most powerful activity against cancer of any clinical trial testing engineered cell therapy to date. This has received international attention, and some of this work has been published recently in Science Translational Medicine and the New England Journal of Medicine.

    In one of my clinical roles, I specialize in the most aggressive form of neuroblastoma, a difficult-to-treat childhood cancer that begins in the peripheral (non-brain) nerve tissue of infants and young children. I work alongside a world-class team of physicians and multi-disciplinary specialists who are dedicated to treating this disease. The neuroblastoma team at CHOP does studies of the patient’s genetics and the unique characteristics of their disease to offer a personalized treatment approach. We were part of the group that did the nationwide clinical trial establishing antibody-based immunotherapy as the new standard of care in neuroblastoma.

    Outside of the clinic, in the lab and the hospital, I am a lab scientist and stem cell transplanter. In the Stem Cell Laboratory we manage cell processing, both collecting the original cells and engineering the cells to the right cell type gets into the patient. I’m also the chair of the Stem Cell Transplant Discipline and transplant clinical trial development for the nationwide Children’s Oncology Group (COG).

    My work in the lab has intersected with my clinical work several times. Working with a group of four institutions, we pioneered a treatment called tandem transplant — two sequential courses of high-dose chemotherapy with stem cell transplant given six weeks apart. This clinical trial was open for about 10 years and helped raise the bar for treating high-risk neuroblastoma. The tandem treatment protocol achieved three-year survival rates of almost 60 percent, three times the survival rate before stem cell transplants, and still the best phase 2 treatment result in the world literature. This tandem transplant approach has been tested in a nationwide phase 3 trial to prove whether it should become the national standard of care, and results should be out soon!

    Similarly, we developed a new class of drugs for acute lymphocytic leukemia (ALL, the most common childhood cancer), based on a target in the ALL cell called mTOR. We have shown that drugs which target mTOR have activity against ALL, and we have taken this treatment to another nationwide phase 3 randomized trial.

    What first brought me to CHOP was the opportunity to conduct transplant and leukemia research, and work in CHOP’s intensely translational environment. Today, I run a lab where the research is devoted to developing molecularly-targeted therapies and cell-based therapies to treat leukemia and solid tumors.

 The goal of all the work I do is to improve treatment options for children with cancer, not just at CHOP but across the U.S. Whether that’s accomplished by offering alternative therapies that are less toxic than today’s standards of care, or advanced treatments for high-risk disease that fight cancer in new and different ways, if we impact the standard of care, I consider that a success.

  • Education and Training

    Medical School

    MD - University of Cincinnati College of Medicine MD, Cincinnati, OH

    Internship

    Pediatrics - Children's Hospital, Boston, MA

    Residency

    Pediatrics - Children's Hospital Fellowships

    Fellowship

    Pediatrics - Harvard Medical School, Boston, MA
    Pediatric Hematology/Oncology - Dana Farber Cancer Institute and Children's Hospital, Boston, MA
    Research Fellow in Immunology - Brigham and Women's Hospital, Boston, MA

    Board Certification

    Pediatric Hematology-Oncology
    Pediatrics

    Graduate Degree

    PhD - University of Cincinnati College of Medicine PhD, Cincinnati, OH

  • Titles and Academic Titles

    Attending Physician

    Director, Cancer Immunotherapy Frontier Program

    Director of Translational Research, Center for Childhood Cancer Research at The Children's Hospital of Philadelphia

    Medical Director, Stem Cell Laboratory

    Director, Stem Cell Biology, Division of Oncology

    Fellowship Program Director, Pediatric Hematology/Oncology

    Deputy Chair, IACUC

    Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Departments and Services
  • Research Interests

    B lymphocyte receptor signaling in leukemia
    Developmental lymphopoiesis
    Stokes research summary

  • Publications

    Books

    Chapters

    2009

    Reid, GSD, SA Grupp and KR Schultz. 2009. Tumor Immunology and immunotherapy. In: Cancer in Children and Adolescents. Chapter 4. WL Carroll and JL Finlay, eds, Jones and Barrett.

    2006

    Grupp, S.A. 2006. Stem Cell Transplantation in Neuroblastoma. In: Pediatric Bone Marrow Transplantation, Chapter 29. R.M. Kline, ed, Taylor and Francis.

    Grupp, S.A. 2006. Issues in Pediatric Stem Cell Collection. In: Pediatric Bone Marrow Transplantation, Chapter 6. R.M. Kline, ed, Taylor and Francis.

    2004

    Grupp, S.A. 2004. Stem cell transplantation in neuroblastoma. In: Neuroblastoma, Chapter 11. S. Cohn and N.K. Cheung, eds, Springer-Verlag.

    2002

    Grupp, S.A. and J. Gorlin. 2002. Pediatric peripheral blood progenitor cell transplantation. In: Pediatric Transfusion Therapy, Chapter 19, pp. 441-470. J.H. Herman and C.S. Manno, eds., American Association of Blood Banks, Bethesda, MD.

    Gorlin, J. and Grupp, S.A. 2002. Transfusion support in pediatric oncology and hematopoietic transplantation. In: Pediatric Transfusion Therapy, Chapter 18, pp. 421-440. J.H. Herman and C.S. Manno, eds., American Association of Blood Banks, Bethesda, MD.

    1998

    Grupp, S.A. and A.K. Abbas. 1998. Humoral immunity and the regulation of immune responses. In: Hematology of Infancy and Childhood, 5th Ed, Chapter 23, pp. 971-989. S. Orkin and D.G. Nathan, eds., Saunders.

    1997

    Grupp, S.A. 1997. Hematologic disorders. In: Manual of Pediatric Therapeutics. N.C., Chapter 15, pp. 431-459. Andrews and J. Graef, eds., Little Brown and Co.

    1986

    Harmony, J.A., A.L. Akeson, B.M. McCarthy, R.E. Morris, D.W. Scupham, S.A. Grupp. 1986. Immunoregulation by plasma lipoproteins. In: The Biochemistry and Biology of Plasma Lipoproteins, Chapter 15, pp. 403-452. Scanu and Spector, eds.

    Abstracts

    2014

    Seif, AE, S Jo, J Altman, H Bassiri, DM Barrett, SA Grupp and GSD Reid.  Epitope spreading is required for long-term protection against acute lymphoblastic leukemia.  56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #3717.

    Richardson, PG, AR Smith, BM Triplett, NA Kernan, SA Grupp, S Arai, JH Antin, LE Lehmann, V Bandiera, RL Hume, AL Hannah, B Nejadnik, RJ Soiffer and Defibrotide Study Group.  Updated results from a large, ongoing, treatment IND study using defibrotide for patients with hepatic veno-occlusive disease.  56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #2470.

    Richardson, PG, NA Kernan, SA Grupp, PL Martin, RJ Soiffer, R Martin, A L Hannah and KF Villa.  Defibrotide for the treatment of severe hepatic veno-occlusive disease: an analysis of clinical benefit as determined by number needed to treat (NNT) to achieve complete response and to improve survival.  56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #2469.

    Frey, NV, BL Levine, SF Lacey, SA Grupp, SL Mude, SJ Schuster, P Shaw, W-T Hwang, MA Wasik, A Obstfeld, M Leung, A Shen, SG Ericson, JJ Melenhorst, CH June and DL Porter.  Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells.  56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #2296.

    V Bhoj, MC Milone, CH June, DL Porter, SA Grupp, JJ Melenhorst, SF Lacey, C Callahan,  J Capobianchi, G Wertheim and Y Mahnke.  Humoral immunity and plasma cell changes in patients responding to CD19-specific chimeric antigen receptor (CAR)-modified T-cell adoptive immunotherapy.  56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #1110.

    Ruella, M, D Barrett, SS Kenderian, O Shestova, TJ Hofmann, J Scholler, SF Lacey, JJ Melenhorst, F Nazimuddin, M Kalos, DL Porter, CH June, SA Grupp, and SI Gill.  Novel chimeric antigen receptor T cells for the treatment of CD19-negative relapses occurring after CD19-targeted immunotherapies. 56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #966.

    Porter, DL, NV Frey, JJ Melenhorst, W-T Hwang, SF Lacey, P Shaw, A Chew, SA Grupp, J Capobianchi, J Gilmore, M Kalos, M Lichtman, L Lledo, AW Loren, Y Manke, KT Marcucci, H McConville, A Shen, PA Wood, Z Zheng, BL Levine and CH June. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed refractory CLL.  56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #1982.

    Porter, DL, SF Lacey, W-T Hwang, P Shaw, NV Frey, SL Maude, JJ Melenhorst, M Lichtman, DT Teachey, A Shen, A Quintas-Cardamas, PA Wood, BL Levine, CH June and SA Grupp.  Cytokine release syndrome (CRS) after chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) CLL.  56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #1983.

    2013

    Gill, S, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, G Danet-Desnoyers, J Scholler, SA Grupp, CH June and M Kalos. Anti-CD123 chimeric antigen receptor T cells (CART-123) provide a novel myeloablative conditioning regimen that eradicates human acute myeloid leukemia in preclinical models. 55th Annual American Society of Hematology, December 7-10, 2013, New Orleans, LA. Blood, Abstract #703.

    Pulsifer, MA, CS Carlson, K Mark, DA Wall, KR Schultz, N Bunin, M Kalos, D Cindy, D Williamson, j Gastier-Foster, MJ Borowitz and SA Grupp.  Striking predictive power for relapse and decreased survival associated with detectable minimal residual disease by IGH VDJ deep sequencing of bone marrow pre- and post- allogeneic transplant in children with B-lineage ALL: A subanalysis of the COG ASCT0431/PBMTC ONC051 study. 55th Annual American Society of Hematology, December 7-10, 2013, New Orleans, LA. Blood, Abstract #731.

    Qin, H, M Cho, W Haso, L Zhang, DM Barrett, RJ Orentas, SA Grupp and TJ Fry.  Pre-clinical development of a novel chimerical antigen receptor targeting high-risk pediatric ALL over-expressing Tslpr. 55th Annual American Society of Hematology, December 7-10, 2013, New Orleans, LA. Blood, Abstract #614.

    Porter, DL, M Kalos, NV Frey, SA Grupp, AW Loren, C Jemison, J Gilmore, H McConville, J Capobianchi, L Lledo, A Chew, A Shen, PA Wood, M Lichtman, Z Zheng, BL Levine and CH June.  Randomized, Phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD 19 (CTL019) in patients with relapsed, refractory CLL. 55th Annual American Society of Hematology, December 7-10, 2013, New Orleans, LA. Blood, Abstract #642.

    Porter, DL, M Kalos, NV Frey, SA Grupp, AW Loren, C Jemison, J Gilmore,H McConville, J Capobianchi, L Lledo, A Chew, Z Zheng, BL Levine and CH June.  Chimeric antigen receptor modified T cells directed against CD19 (CTL019) have long-term persistence and induce durable responses in relapsed, refractory CLL. 55th Annual American Society of Hematology, December 7-10, 2013, New Orleans, LA. Blood, Abstract #642.

    Kalos, M, F Nazimuddin, JM Finklestein, M Gupta, I Kulikovskaya, DE Ambrose, S Gill, SF Lacey, Z Zheng, JJ Melenhorst, BL Levine, NV Frey, SA Grupp, DL Porter and CH June.  Long-term functional persistence, B cell aplasia and anti-leukemia efficacy in refractory B cell malignancies following T cell immunotherapy using CAR-redirected T cells targeting CD19. 55th Annual American Society of Hematology, December 7-10, 2013, New Orleans, LA. Blood, Abstract #801.

    Papers

    2015

    Porter, DL, WT Hwang, NV Frey, SF Lacey, PA Shaw, AW Loren, A Bagg, KT Marcucci, A Shen, V Gonzalez, D Ambrose, SA Grupp, A Chew, Z Zheng, MC Milone, BL Levine, JJ Melenhorst, CH June. 2015. Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia. Science Translational Medicine. In press.

    Haiying, Q, M Cho, W Haso, L Zhang, S Tasian, H Zarni Oo, G Neri, Y Lin, J Zhou, B Mallon, S Maude, D Teachey, D Barrrett, R Orentas, M Daugaard, P Sorensen, SA Grupp, and T Fry. 2015. Eradication of pre B cell ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. In press.

    Pulsipher, MA, C Carlson, B Langholz, DA Wall, KR Schultz, N Bunin, I Kirsch, JM Gastier-Foster, M Borowitz, C Desmarais, D Williamson, M Kalos, and SA Grupp. 2015. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood, in press. DOI 10.1182/blood-2014-12-615757.

    Pulsipher, MA, B Langholz, DA Wall, KR Schultz, N Bunin, W Carroll, E Raetz, S Gardner, RK Goyal, J Gastier-Foster, M Borowitz, D Teachey, and SA Grupp. 2015. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplantation. In press. doi:10.1038/bmt.2015.103

    Maude, SL, DT Teachey, DL Porter, and SA Grupp. 2015. CD19-targeted Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Blood, in press.

    Maude, SL, S Dolai, C Delgado-Martin, TL Vincent, A Robbins, A Selvanathan, T Ryan, J Hall, AC Wood, SK Tasian, SP Hunger, ML Loh, CG Mullighan, BL Wood, ML Hermiston, SA Grupp, RB Lock, and DT Teachey. 2015. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood, in press.

    2014

    Grupp, SA. 2014. Advances in T-cell therapy for ALL. Best Practice & Research Clinical Haematology, doi:10.1016/j.beha.2014.10.014

    Yanik, GA, SA Grupp, MA Pulsipher, JE Levine, KR Schultz, DA Wall, B Langholz, CC Dvorak, K Alangaden, RK Goyal, ES White, JM Collura, MA Skeens, S Eid, EM Pierce, and KR Cooke. 2014. TNF receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome (IPS). A joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Children’s Oncology Group (COG) study (ASCT0521). Biol. Blood and Marrow Trans. In press.  PMID: 25270958.

    Lee, DW, R Gardner, DL Porter, CU Louis, N Ahmed, M Jensen, SA Grupp, and CL Mackall, C. L. 2014, Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2): 188-195. PMID: 24876563.

    Lankester, AC, F Locatelli, P Bader, E Rettinger, M Egeler, S Katewa, MA Pulsipher, S Nierkens, K Schultz, R Handgretinger, SA Grupp, JJ Boelens, and CM Bollard. 2014. Will post transplant cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant. DOI: 10.1016/j.bbmt.2014.07.018; S1083-8791(14)0044-3. PMID: 25064748.

    June, CH, MV Maus, G Plesa, LA Johnson, Y Zhao, BL Levine, SA Grupp, and DL Porter. 2014. Engineered T cells for cancer therapy. Cancer Immunol Immunother., DOI: 10.1007/s00262-014-1568-1. Sep673(9):969-75.  Epub 2014 June 19. PMID: 24943274

    Cutler, C,  B Logan, B, R. Nakamura, L Johnston, S Choi, D. Porter, WJ Hogan, M Pasquini, ML MacMillan, J Hsu, EK Waller, SA Grupp, P McCarthy, J Wu, ZH Hu, SL Carter, MM Horowitz, JH Antin. 2014. Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood. 8 Aug. 21; 124(8):1372-7. Doi: 10.1182/blood-2014-04-567164, Epub 2014 June 30. PMID: 24982504.

    Singh, NA, X Liu, J Hulitt, S Jiang, CH June, SA Grupp, DM Barrett, and Y Zhao. 2014. Nature of tumor control by permanently and transiently-modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunology Research. DOI: 10.1158/2326-6066.CIR-14-0051.

    Maude, SL N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, VE Gonzalez, Z Zheng, SF Lacey, BL Levine, YD Mahnke, JJ Melenhorst, SR Rheingold, A Shen, DT Teachey, CH June, DL Porter, and SA Grupp. 2014. Sustained Remissions with Chimeric Antigen Receptor T Cells For Leukemia. New England Journal of Medicine, 371:1507-17.  PMID: 25317870.  NIHMSID: 640298.

    Pulsipher, MA, B Langholz, DA Wall, KR Schultz, N Bunin, W Carroll, E Raetz, S Gardner, RK Goyal, J Gastier-Foster, M Borowitz, DT Teachey, and SA Grupp. 2014. The Role of Acute Graft versus Host Disease and Minimal Residual Disease in Predicting Risk of Relapse after Allogeneic Transplantation for Childhood ALL:  Subanalysis of a Phase III Trial COG ASCT0431/PBMTC ONC051. Blood, in press. PMID: 24497539; PMCID: 3968388.

    Pulsipher, MA, B Langholz, DA Wall, KR Schultz, N Bunin, WL Carroll, E Raetz, S Gardner, JM Gastier-Foser, D Howrie, RK Goyal, JG Douglas, M Borowitz, Y Barnes, DT Teachey, C Taylor, SA Grupp. 2014. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: A phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood, Blood 123(13): 2017-2025.

    Bassiri, H, R Das, P Guan, DM Barrett, PJ Brennan, PP Banerjee, SJ Wiener, JS Orange, MB Brenner, SA Grupp, KE Nichols. 2014. iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo. Cancer Immunol Res, Jan 1; 2(1):59-69, doi: 10.11578/2326-6066.CIR-13-0104. PMID: 24563871; PMCID: 3927984; NIHMS: 542978.

    Gill, S, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, G Danet-Desnoyers, J Scholler, SA Grupp, CH June, and M Kalos. 2014. Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptor-modified T cells. Blood. Published ahead of print March 4, 2014, doi:10.1182/blood-2013-09-529537. PMID: 24596416; PMCID: 3983612.

    Maude, SL, DM Barrett, DT Teachey, and SA Grupp. 2014. Managing cytokine release  syndrome associated with novel T cell engaging therapies. Cancer J, March/April, 20(2):119-122. Doi.1097/PPO.0000000000000035. PMID: 24667956. NIHMS: 607703. PMCID: 4119809.

    Maus, MV, SA Grupp, DL Porter, and CH June. 2014. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. Epub ahead of print. PMID: 24578504; PMCID: 3999751.

    Barrett, DM, N Singh, DL Porter, SA Grupp and CH June. 2014. Chimeric antigen receptor therapy for cancer. Ann Rev Med. Jan 14;65:333-47. Doi: 10.1146/annurev-med-060512-150254. Epub 2013 Nov 20. PMID: 24274181.  NIHMS: 607694. PMCID: 4120077.

    Barrett, DM, N Singh, X Liu, S Jiang, CH June, SA Grupp and Y Zhao. 2014. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.  Cytotherapy. Jan 15. pii:S1465-3249(13)00759. Doi:10.1016/j.jcyt.2013.10.013. [Epub ahead of print]  PMID: 24439255; PMCID: 3988256; NIHMS: 559247.

    Barrett, DM, DT Teachey, and SA Grupp. 2014. Toxicity Management for Patients Receiving Novel T-cell Engaging Therapies. Current Opinion on Pediatrics. Feb, 26(1):43-9. Doi: 10.1097/MOP.0000000000000043.  PMID: 24362408. NIHMS: 607686. PMCID: 4198063.

    2013

    Teachey, DT, SR Rheingold, SL Maude, G Zugmaier, DM Barrett, AE Seif, KE Nichols, EK Suppa, M Kalos, RA Berg, JC Fitzgerald, R Aplenc, L Gore, and SA Grupp. 2013. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 121(26):5154-5157. Doi: 10.1182/blood-2013-02-485623. Epub 2013 May 15. PMID: 23678006. NIHMS: 607684.  PMCID: 4123427.

    Barrett, DM, X Liu, S Jiang, CH June, SA Grupp*, and Y Zhao*. 2013. Regimen specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Human Gene Therapy, 24(8):717-27. Doi: 10.1089/hum.2013.075.  PMID: 23883116.  PMCID: 374289.
    *equal contribution

    Schultz, RK, KS Baker, JJ Boelens, CM Bollard, RM Egeler, M Cowan, R Ladenstein, A. Lankester, F Locatelli, A Lawitschka, JE Levine, M Loh, E Nemecek, C Niemeyer, VK Prasad, V Rocha, S Shenoy, B Strahm, P Veys, D wall, P Bader, SA Grupp, MA Pulsipher, and C Peters. 2013. Challenges and opportunities for international cooperative studies in pediatric hematopoietic cell transplantation priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant, Sep. 19(9):1279-87. Doi: 10.1016/j.bbmt.2013.07.006. Epub 2013 Jul 21. PMID: 23883618. NIHMS: 607798. PMCID: 4198148.

    Kreissman, SG, RC Seeger, KK Matthay, WB London, R Sposto, SA Grupp, DA Haas-Kogan, MP LaQuaglia, AL Yu, L Diller, A Buxton, JR Park, SL Cohn, JM Maris, CP Reynolds, and JG Villablanca. 2013. Prospective, Randomized Trial of Purged versus Non-Purged Peripheral Blood Stem Cell Transplant for High Risk Neuroblastoma. Lancet Oncology, 14(10):999-1008.  PMID: 23890779 ; PMCID: 3963485; NIHMS: 540046.

    Grupp, SA, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, DT Teachey, BL Levine, and CH June. 2013. Induction of complete remissions of ALL by chimeric antigen receptor-expressing T cells. New England Journal of Medicine. 368(16):1509-18. PMID: 23527958;  PMCID: 4058440; NIHMS: 474709.

    Posters and Presentations

    2014

    Grupp, SA, SL Maude, P Shaw, R Aplenc, DM Barrett, C Callahan, A Chew, SF Lacey, BL Levine JJ Melenhorst, L Motley, SR Rheingold, A Shen, DT Teachey, PA Wood, DL Porter and CH June.  T cells engineered with a chimeric antigen receptor targeting CD19 (CTL019 cells) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. 56th Annual American Society of Hematology, December 6-9, 2014, San Francisco, CA.  Blood, Abstract #380.
    *Platform presentation by Dr. Grupp
    *Featured in ASH Press Program
    *Featured in Best of ASH

    Grupp, SA, N Frey, R Aplenc, B Levine, S Maude, S Rheingold, C. Strait Barker, D Teachey, Y Mahnke, D Porter, C June. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019 cells) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. 40th European Bone Marrow Transplant Meeting, April 2014, Milan, Italy, Abstract #1.
    * Winner, van Bekkum Prize
    1st Plenary Abstract Presentation

    2013

    Grupp, SA, NV Frey, R Aplenc, DM Barrett, A Chew, M Kalos, BL Levine, M Lichtman, SL Maude, SR Rheingold, A Shen, C Strait, DT Teachey, PA Wood, D Porter and CH June.  T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without Gvhd in children and adults with relapsed, refractory ALL. 55th Annual American Society of Hematology, December 7-10, 2013, New Orleans, LA. Blood, Abstract #614.
    *Platform presentation by Dr. Grupp
    *Featured in ASH Press Program

    Invited Lectures

    2015

    “Functional determinants of highly active cell therapy”, European Hematology Association, Vienna, Austria (June)

    “Cell therapy for pediatric ALL”, Canadian Society for Immunology, Winnipeg, Canada (June)

    Session Chair, ASCO Session on Emerging Topics in Immunotherapy and Cellular Therapy; “Immunotherapy for Childhood Leukemia”, ASCO, Chicago, IL (May)

    “Cell therapy for leukemia crosses the activity threshold”, Fred Saunders Award and Lectureship, Canadian Blood and Marrow Transplant Group, Montreal, Canada (May)

    “Adoptive Cell Therapy with Engineered T Cells”, Hematology Grand Rounds, Boston Children’s Hospital, Boston, MA (May)

    “Highly Active Cell Therapy in Pediatric Cancer”, Grand Rounds, Children’s Hospital, Philadelphia PA (May)

    “Highly Active Cell Therapy in Pediatric Cancer”, CHOP Research Institute Symposium, Children’s Hospital, Philadelphia PA (May)

    “Novel Therapies in Pediatric Leukemia”, Frank Oski Memorial Lectureship and Award, ASPHO Meeting, Phoenix, AZ (May)

    “Cell therapy for leukemia crosses the activity threshold”, Grand Rounds, MD Anderson Cancer Center, Houston, TX (April)

    “Cell therapy for leukemia, the pediatric story”, Barcelona Cell Therapy Symposium, Barcelona, Spain (March)

    “Cell therapy for leukemia crosses the activity threshold”, Cancer Center Grand Rounds, University of Wisconsin, Madison, WI (March)

    “Highly Active Cell Therapy of B Cell Malignancies”, Grand Rounds, University of Wisconsin, Madison, WI (March)

    “Cellular Therapies: Breakthrough Treatment?” American Society of Bone Marrow Transplantation Tandem Meeting, San Diego, CA (February)

    “Cell therapy for leukemia crosses the activity threshold”
    “CAR T cells: preclinical models and novel applications”, Kuwait International Pharmacy Conference, Kuwait City, Kuwait (February)

    2014

    “T Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 (CTL019 cells) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL”
    (above abstract featured and presented in ASH Press Program)
    (above abstract featured at Best of ASH Program)
    “Chimeric Antigen Receptor (CAR) T Cell Therapy for Leukemia”
    American Society of Hematology Annual Meeting, San Francisco, CA (December)

    “Impact of proliferation and persistence on successful T cell therapy”, Dana Farber Cancer Institute, Boston, MA (December)

    “Update on highly active CAR T cell therapy for leukemia”, CCCBD Grand Rounds, Children’s Hospital of LA, Los Angeles, CA (November)

    “Engineered Cell Therapy: A new paradigm in cancer therapy”, NMDP Annual Meeting, Minneapolis, MN (November)

    “Engineered Cell Therapy: A new paradigm in cancer therapy”, Keynote Speaker, Leukemia and Lymphoma Society Meeting, Tampa, FL (October)

    “Update on Engineered Cell Therapy for ALL”, American Association of Blood Banking Annual Meeting, Philadelphia, PA (October)

    “Update on Engineered Cell Therapy for ALL”, Society for Adolescent and Young Adult Oncology, Irvine, CA (October)

    “CAR T Cells Cross the Activity Threshold”, Alex’s Lemonade Stand Foundation Annual Investigators Meeting, Philadelphia, PA (October)

    “CAR T Cells Cross the Activity Threshold”, University of Chicago Oncology Grand Rounds, Chicago IL (October)

    “Update on Engineered Cell Therapy for ALL”, CHAMI, Ann Arbor, MI (September)

    “Cell therapy for leukemia crosses the activity threshold”, Wilsede Leukemia Meeting, Hamburg, Germany (June)

    “CART19 for pediatric ALL – an update”, British Society for Bone Marrow Transplantation, London, England (May)

    “Cell therapy for acute leukemia”, Acute Leukemia Forum, San Francisco, CA (May)

    “Cell therapy for leukemia crosses the activity threshold”, Dartmouth Immunology Annual Symposium, Dartmouth, NH (May)

    “Cell therapy for leukemia crosses the activity threshold”, AACR Invited Talk, AACR Annual Meeting, San Diego, CA (April)

    “T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL” “New frontiers in cellular therapy for lymphoid malignancies” European Bone Marrow Transplant Meeting, Milan, Italy (April)

    “Cell therapy for leukemia crosses the activity threshold”, Johnson and Johnson Annual Research Summit, Lancaster, PA (April)

    “Chimeric Antigen Receptor (CAR) T Cells: A bridge to SCT or a replacement for SCT?” Societe Française d'Hematologie, Paris, France (March)

    “Meet the Professor: Neuroblastoma” “Update on CAR Therapy for ALL” American Society of Bone Marrow Transplantation Tandem Meeting, Dallas, TX (February)

    2013

    “T Cells Engineered With a CAR Targeting CD19 Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without GVHD In Children and Adults With Relapsed, Refractory ALL”
    (above abstract featured and presented in ASH Press Program) “Chimeric Antigen Receptors (CARs): Driving Immunotherapy!” American Society of Hematology Annual Meeting, New Orleans, LA (December)

    “The ASCT1221 Study: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to SCT for Children with JMML,” JMML Foundation Meeting, New Orleans, LA (December)

    “Highly Active Cell Therapy of B Cell Leukemia,” Yonsei University/Severance Hospital, Seoul, South Korea (October)

    “Highly Active Cell Therapy of B Cell Leukemia,” “CAR T cells: preclinical models and novel applications,” The 7th International Conference on Cell Therapy, Seoul, South Korea (October)

    “Highly Active Cell Therapy of B Cell Leukemia,” Seoul National University Hospital Grand Rounds, Seoul, South Korea (October)

    “Use of Modified HIV to Engineer Cells: a possible cure for leukemia?,” ATHEM meeting, Lille, France (October)

    “Highly Active Cell Therapy of B Cell Leukemia,” “CAR T cells: preclinical models and novel applications,” Stanford University Grand Rounds and Pediatric Oncology Research Conference, Palo Alto, CA (October)

    “Highly Active Cell Therapy of Leukemia - Another way to get GVL w/o GVHD,” Pediatric Blood and Marrow Transplant Consortium Research Conference, Dallas TX (October)

    “Cellular therapies post SCT - Pros and cons,” Speaker and Session Chair, SIOP Annual Meeting, Hong Kong (September)

    “Highly Active Cell Therapy of Pediatric Leukemia,” Curesearch Conference, Washington, DC (September)

    “CAR T cells: preclinical models/novel applications,” Research Steering Committee
    “Update on CHP959”, Novartis Alliance Retreat, Philadelphia, PA (September)

    ASBMT Research Training Course, Santa Fe, NM (Program faculty, multiple lectures/sessions) (July)

    “Highly Active Cancer Cell Therapy,” Keynote Speaker, Chinese Biopharmaceutical Association, Conference, Rockville, MD (June)

    “Highly Active Cell Therapy of Pediatric Leukemia,” UMN BMT Conference, Minneapolis, MN (May)

    “CTL019 Clinical Updates on Pediatric ALL,” Novartis, East Hanover, NJ (March)

    “Update on CART19,” Leukemia/Lymphoma Retreat, Division of Oncology, CHOP

    “Harnessing the Immune System: Highly Active Cell Therapy of Pediatric Cancer,” Delaware Valley APHON Conference, Radnor, PA (April)

    “Highly Active Cell Therapy of Pediatric Leukemia,” CHOP Faculty Conference, Philadelphia, PA (March)

    “Highly Active Adoptive Cell Therapy of Leukemia – Update on CART19,” DGGT German Gene Therapy Group, Hamburg, Germany (February)

    “Highly Active Cell Therapy of B Cell Malignancies,”
    “CAR T cells: preclinical models and novel applications,” BMS/Navarre Immunotherapy Conference, Pamplona, Spain (February)

    “Highly Active Cell Therapy for Pediatric Cancer,” Brigham and Women’s Hospital Grand Rounds, Boston, MA (February)

    “Cell Therapy as Personalized Medicine in Pediatric Cancer,” Cutting-Edge Medicine in Everyday Practice, Princeton, NJ (January)

    “Highly Active Cell Therapy for Leukemia,” Robert Wood Johnson Oncology Grand Rounds, New Brunswick, NJ (January)

  • Awards and Honors

    2015, Fred Saunders Lectureship and Award, Canadian Blood and Marrow Transplant Society
    2015, Oski Lectureship and Award, American Society of Pediatric Hematology/Oncology
    2014, Audrey Evans Service Award, Ronald McDonald House Charities
    2014, van Bekkum Prize, European Bone Marrow Transplantation Society
    2014, Clinical Research Forum Herbert Pardes First Place Achievement Award
    2014, Clinical Research Forum Top 10 Clinical Research US Achievement Award
    2014, Pennsylvania Bio Patient Impact Award
    2013, Visiting Professor, Stanford University, Stanford, CA
    2013, Chai Lifeline Community Service Award
    2012, Yetta Deitch Novotny Chair, CHOP
    2011-2014, Elected to the ASPHO Board of Trustees
    2010, Elected to American Pediatric Society
    2009, Transplantation Visiting Professor, Hospital for Sick Children and University of Toronto, Toronto, Canada
    2008, W.E. Hathaway Visiting Professor, University of Colorado, Denver, CO
    2008, Aflac Visiting Professor, Emory University and Children’s Healthcare of Atlanta, Atlanta, GA
    2007, Eagles Fly for Leukemia 2007 Lifetime Achievement Award
    2003, Elected to the Society for Pediatric Research
    2002, Research Recognition Award, Leukemia and Lymphoma Society, Philadelphia, Pennsylvania
    2000-2005, Stanford Young Investigator in Molecular Oncology
    1997, 1997 Research Award, 5th International Meeting on Blood Cell Transplantation, Omaha, Nebraska
    1993-1996, 1993-96 Amy C. Potter Fellow
    1987, Bogen Award for Outstanding Medical Student Research, University of Cincinnati College of Medicine
    1986, Research Award, Midwest Medical Research Forum, University of Michigan
    1981, Graduated Magna cum Laude - University of Cincinnati, Cincinnati, OH

  • Editorial and Academic Positions

    Editorial Positions

    Reviewer

    NIH and ACS study sections (ad hoc reviewer)
    NIH P01 Study Sections
    Journal of Clinical Oncology
    Lancet
    Journal of Immunology
    Journal of Pediatrics
    Journal of Pediatric Hematology/Oncology
    Journal of Clinical Investigation
    Blood
    British Journal of Hematology
    Cancer Research
    Clinical Cancer Research

    Academic and Institutional Committees

    1998-present, Therapeutic Standards Committee
    1996-present, Institutional Animal Care and Use Committee
     - 2003-present, deputy chair

  • Leaderships

    Memberships in Professional Organizations

    International

    2014-present, International Society for Cell Therapy

    National

    2010-present, American Pediatric Society
    2003-present, Society for Pediatric Research
    2001-present, American Society of Pediatric Hematology/Oncology
    2001-present, American Association for Cancer Research
    1998-present, American Society of Hematology
    1996-present, American Society of Blood and Marrow Transplantation
    1995-present, Fellow of the American Academy of Pediatrics
    1992-present, American Association for the Advancement of Science